- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00212901
High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy
July 25, 2007 updated by: Ottawa Hospital Research Institute
Addition of Angiotensin Receptor Blockade to ACE Inhibition Versus High Dose ACE Inhibition for Reduction of Proteinuria in Patients With Diabetic Nephropathy
Investigation of wheather addition of angiotensin receptor blocker (Irbesartan) to recommended doses of angiotensin converting enzyme inhibitor (trandolapril) is more effective in decreasing amount of protein in urine in patients with diabetic kidney disease than high doses of trandolapril.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 7W9
- The Ottawa Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Early diabetic nephropathy as defined by proteinuria between 500mg/24hr and 3g/24hr and GFR>50ml/min (as calculated by the Cockcroft-Gault formula), in the absence of clinical and laboratory evidence of other non-diabetic renal disease.
- Controlled blood pressure (<150/<90)
- Able to give informed consent
- Between the ages of 18 and 75
- Must be capable of providing a 24 hour urine collection
- Negative BHcG test for ruling out pregnancy in women of childbearing age
Currently taking an angiotensin converting enzyme inhibitor
-
Exclusion Criteria:
- Creatinine clearance <50ml/min or 24hour protein excretion >3gm/d.
- Hypotension as defined by the inability to add an ARB or increase ACE-I dose secondary to hypotensive symptomatology or a systolic Bp <100mmHg.
- Serum potassium >5.5 on two separate occasions in the previous six months
- Previous adverse reaction to angiotensin receptor antagonist medication
- Use of NSAIDS including COX2 inhibitors
- Pregnant or nursing women will be excluded
Currently taking an angiotensin receptor antagonist
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
reducing proteinuria
|
Secondary Outcome Measures
Outcome Measure |
---|
glomerular filtration rate
|
side-effects of hypotension, postural symptom
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Ayub Akbari, MD, OHRI
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2004
Study Completion (ACTUAL)
September 1, 2006
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (ESTIMATE)
September 21, 2005
Study Record Updates
Last Update Posted (ESTIMATE)
July 26, 2007
Last Update Submitted That Met QC Criteria
July 25, 2007
Last Verified
July 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2004482-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Kidney Disease
-
University of UtahNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingHemodialysis | Kidney Disease, Chronic | Kidney Failure | Dialysis | Diabetic | End-stage Kidney Disease | Kidney Dysfunction | Non-diabeticUnited States
-
Eli Lilly and CompanyTerminatedDiabetic Nephropathy | Diabetic Kidney Disease | Diabetic GlomerulosclerosisIsrael, Hungary, United States, Australia, France, Czechia, Puerto Rico
-
Chinese PLA General HospitalBeijing Friendship Hospital; Guang'anmen Hospital of China Academy of Chinese... and other collaboratorsRecruitingDiabetic Kidney DiseaseChina
-
Omar Tarek ElfarargiNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...Second Affiliated Hospital of Wenzhou Medical University; Lishui Country People...Not yet recruitingEstablishment and Clinical Validation of a New Technique for Early Diagnosis of Diabetic NephropathyDiabetes Mellitus | Diabetic Kidney Disease | Biomarkers | Early Diagnosis
-
Fayoum UniversityCairo UniversityNot yet recruitingSGLT2i Kideny Protection Against Contrast in Diabetic Kidney
-
Mayo ClinicRegenerative Medicine MinnesotaTerminatedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Kidney Disease | Diabetic Nephropathies | Chronic Kidney Disease | Kidney Failure | Diabetic Nephropathy Type 2 | Kidney InsufficiencyUnited States
-
CSL BehringCompletedDiabetic Kidney Disease (DKD)United States, Australia, New Zealand, Puerto Rico, Canada, Israel
-
The First Affiliated Hospital of Xiamen UniversityNot yet recruitingDiabetic Nephropathies
-
University of LeedsLund University; University of Turku; University Hospital, Bordeaux; University... and other collaboratorsRecruitingDiabetic Kidney DiseaseFinland, France, Italy, Sweden, Switzerland, United Kingdom
Clinical Trials on High dose ACE-I vs ARB
-
Stiftung Institut fuer HerzinfarktforschungNovartis PharmaceuticalsCompleted
-
Soroka University Medical CenterCompleted
-
Tata Memorial HospitalCompletedCervical Cancer | Cervix Cancer | Cancer of Cervix | Cancer of the CervixIndia
-
Hakeam Abdulaziz HakeamKing Khalid University Hospital; Princess Nourah Bint Abdulrahman University; Buraidah Central HospitalCompleted
-
Mashhad University of Medical SciencesUnknownGraves' DiseaseIran, Islamic Republic of
-
Hippocration General HospitalCompletedCoronary Artery Disease | Atherosclerosis | Endothelial Dysfunction | Oxidative Stress | HMG-CoA Reductase Inhibitor ToxicityGreece
-
National Institute of Diabetes and Digestive and...Washington University School of Medicine; Merck Sharp & Dohme LLC; University... and other collaboratorsCompleted
-
Kaohsiung Veterans General Hospital.E-DA HospitalRecruitingMitral Regurgitation | Systolic Heart Failure Stage D (Disorder)Taiwan
-
Soroka University Medical CenterCompletedRadiographic Contrast Agent Nephropathy
-
National Institute of Diabetes and Digestive and...Washington University School of Medicine; Merck Sharp & Dohme LLC; University... and other collaboratorsCompleted